Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

413ec843e87e7f1d18e42dbf.l2vrXEOcv9nE2hE8ADz6M8bO7SjuTtO7WRVKNyAW4oI.pQ-4GBvTya-btVBYeWSWAK-Dh12nJpLuCCMpQG1_ju7OXbM_CcPKtpzrZg~9819b95383457f9a77f0fd42e7a42458
09/07 BMO Capital Initiates CONMED at Market Perform With $36 Price Target MT
29/06 CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says MT
29/06 BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target MT
18/05 BofA Securities Adjusts CONMED Price Target to $40 From $52 MT
17/03 Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55 MT
12/25/12 Conmed Shares Fall After Needham Downgrade MT
12/25/12 Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target MT
28/25/28 Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75 MT
06/25/06 JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85 MT
01/24/01 Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating MT
25/24/25 Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating MT
25/24/25 Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating MT
25/24/25 Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating MT
01/24/01 Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating MT
01/24/01 JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating MT
27/23/27 Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating MT
26/23/26 Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating MT
27/23/27 Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating MT
27/23/27 Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating MT
05/23/05 Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating MT
22/23/22 CL King Starts CONMED at Buy With $140 Price Target MT
27/23/27 Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating MT
27/23/27 Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating MT
27/23/27 Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating MT
27/23/27 Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+10.39%
+13.31%
+11.34%
+28.27%
+8.36%
+25.7%
+15.11%
+19.86%
+9.65%
Average +15.78%
Weighted average by Cap. +13.98%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
44.25USD
Average target price
39.00USD
Spread / Average Target
-11.86%
High Price Target
40.00USD
Spread / Highest target
-9.60%
Low Price Target
36.00USD
Spread / Lowest Target
-18.64%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BMO Capital
BofA Securities
Piper Sandler
Needham & Co.
Stifel Nicolaus
JPMorgan Chase
Wells Fargo Securities
KeyBanc Capital Markets
CL King
Jefferies & Co.
UBS
Barclays
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
44.25USD
Average target price
39.00USD
Spread / Average Target
-11.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNMD Stock
  4. EC8 Stock
  5. Consensus CONMED Corporation